Navigation Links
AcelRx Pharmaceuticals to Host Investor Day on June 27, 2013
Date:6/21/2013

REDWOOD CITY, Calif., June 21, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, will host an Investor Day on Thursday, June 27, 2013, from 9:00 a.m. to 11:00 a.m. EDT (6:00 a.m. to 8:00 a.m. PDT) at the 21 Club, 21 West 53rd Street, New York, NY.

Members of the AcelRx management team will present insights on the Company's Sufentanil NanoTab PCA System Phase 3 clinical trial results and discuss plans related to hospital formulary adoption and commercialization. In addition, thought leaders who treat post-operative pain in the hospital setting will discuss their experience with and perspectives on the Sufentanil NanoTab PCA System. Breakfast will be served for meeting attendees from 8:00 a.m. to 9:00 a.m. and a link to the live webcast will be available on the Investors page of the Company's website at www.acelrx.com beginning at 9:00 a.m. EDT. An archive of the webcast will be available shortly after the event through the Investors page at www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.  AcelRx's lead product candidate, the Sufentanil NanoTab PCA System, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. The NanoTab System has
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
2. AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results
3. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
4. AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
5. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
6. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
7. AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
8. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
9. AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. AcelRx Pharmaceuticals Provides Clinical Trial Updates
11. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014 Depomed, Inc. (NASDAQ: ... the Piper Jaffray 26 th Annual Healthcare Conference in ... the Piper Jaffray conference is scheduled for 8:00 am EST (5:00 ... webcast, and the webcast can be accessed via the Investor Relations ... of the webcast will be archived for 30 days on the ...
(Date:11/21/2014)... Nov. 20, 2014 Oxis International, Inc. (OXIS) (OXI.PA) ... election of Anthony J. Cataldo as Chief Executive ... Effective November 19, 2014, Ken Eaton resigned his ... of Directors of Oxis International, Inc. to pursue new opportunities. ... named Chief Executive Officer of Oxis International, Inc. Mr. Cataldo ...
(Date:11/21/2014)... Texas , Nov. 21, 2014  Lexicon Pharmaceuticals, ... pricing of its previously announced underwritten public offering of ... an effective shelf registration statement. The offering will consist ... offering price of $1.005 per share.  Lexicon has also ... to 7,462,687 additional shares of common stock.  All of ...
Breaking Medicine Technology:Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2OXIS International, Inc. announces Changes in Management Team 2OXIS International, Inc. announces Changes in Management Team 3Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3
... CPHD ) today announced that Robert Kwiatkowski, ... of Infectious Disease Research and Development, reporting to David ... impressive menu of eleven highly regarded Xpert® tests for ... extend our leadership with next-generation products, including a number ...
... BETHLEHEM, Pa., June 22, 2011 In a ... of diazepam (NRL-1) achieved positive clinical results in ... was designed and manufactured at Particle Sciences.  In ... pharmacokinetic profile comparable to that reported in the ...
Cached Medicine Technology:Cepheid Appoints Vice President of Infectious Disease Research & Development 2Cepheid Appoints Vice President of Infectious Disease Research & Development 3Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis' Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam) 2
(Date:11/23/2014)... 23, 2014 Locks-Magnetic.com, a notable magnetic ... Moreover, all the new products are available at low ... manager is proud of the new emergency doors. The ... And customers can choose from several colors. All of ... quality emergency door release is not as easy as ...
(Date:11/23/2014)... November 23, 2014 SWAccessControl.com's high quality ... market. Recently, the company has announced its new collection ... offer on these high quality power suppliers. All the ... off. The special offer lasts until Dec. 20, 2014. ... of them have been supporting it for a long ...
(Date:11/23/2014)... Asher Milgrom, is a celebrity doctor ... was recently featured on International Business Times. ... of American Medical Aesthetics & Wellness, also known as ... scholarship to attend an M.D./Ph.D program at University of ... of Chicago, where his field of study was neuro-biochemistry. ...
(Date:11/23/2014)... November 23, 2014 Syngenta lawsuits are ... behalf of farmers and agribusinesses that have allegedly incurred ... commercialize Agrisure Viptera and Agrisure Duracade, genetically modified ... approved for sale in China. According to a report ... virtually ban U.S. corn imports. Because China is the ...
(Date:11/23/2014)... City, Utah (PRWEB) November 23, 2014 ... health insurance reimbursement for small businesses, announced their ... book, The End of Employer-Provided Health Insurance. ... insurance is the greatest financial risk facing most ... facing U.S. employers, small and large, when it ...
Breaking Medicine News(10 mins):Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 2Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 3Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2
... active may help to tackle health threats, study says ... large body size, former professional football players aren,t at ... that looked at 201 retired NFL players. , The ... group of men from the population-based Dallas Heart Study ...
... -- The angiotensin system inhibitor irbesartan did not improve outcomes ... left ventricular ejection fraction. -- ... predominantly affects women and older patients; ... therapies is critical. NEW ORLEANS, Nov. 11 An angiotensin ...
... prevention trial on low-dose aspirin in diabetics,Japanese investigators report ... preventing the primary endpoints of all atherosclerotic events,although it ... - Low-dose aspirin was also associated with a reduced ... a subgroup of diabetics who,were over age 65., ...
... highlights:, -- Individually tailored doses of ... month as measured by platelet reactivity,monitoring by ... measures a,patient,s anti-platelet response to clopidogrel., ... bleeding events,between treatment and control groups., ...
... Study highlights:, - In a randomized, double-blind study ... C-reactive protein (hsCRP) greater than or equal to,2, those ... 31 heart attacks,and 33 strokes compared to 68 and ... analysis showed similar findings across gender, race,ethnicity and Framingham ...
... N.J., Nov. 11, 2008) The F.M. Kirby Foundation of ... Nursing at Rutgers, The State University of New Jersey, to ... Jersey residents. , The grant will also fund the work ... and service in the best academic tradition, said Interim Dean ...
Cached Medicine News:Health News:Retired NFL Players Don't Face Greater Heart Risk 2Health News:Heart Failure Patients With Normal Left Ventricular Ejection Fraction Don't Benefit From Treatment With Angiotensin II Receptor Blocker 2Health News:Heart Failure Patients With Normal Left Ventricular Ejection Fraction Don't Benefit From Treatment With Angiotensin II Receptor Blocker 3Health News:Type 2 Diabetics Studied in Low-Dose Aspirin Trial 2Health News:Type 2 Diabetics Studied in Low-Dose Aspirin Trial 3Health News:Type 2 Diabetics Studied in Low-Dose Aspirin Trial 4Health News:Tailored Drug Delivery Reduces Adverse Effects After PCI 2Health News:Tailored Drug Delivery Reduces Adverse Effects After PCI 3Health News:Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein 2Health News:Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein 3Health News:Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein 4Health News:Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein 5
EPO EIA Human Cytokines 021-SDX021 Erythropoietin Anemia...
Calcitonin EIA Bone and Mineral Metabolism 021-SDX017...
... an enzyme immunoassay (EIA) kit for the ... the subclass of Anti-Neutrophil Cytoplasmic Antibodies (ANCA) ... an aid in the diagnosis of crescentic ... with vasculitic disorders and glomerulonephritis (GN). They ...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase...
Medicine Products: